Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Cefiderocol is a cephalosporin antibiotic used in complicated urinary tract infections. Cefiderocol is a cephalosporin antibacterial drug and exerts a mechanism of action similar to other β-lactam antibiotics.
- Mechanism
- Curator reviewed
Cefiderocol acts by binding to and inhibiting penicillin-binding proteins (PBPs), preventing cell wall synthesis and ultimately causing death of the bacterial cell. Like other β-lactam antibiotics cefiderocol is able to enter bacterial cells via passive diffusion through porins. Unlike other β-lactams, cefiderocol contains a chlorocatechol group which allows it to chelate iron. Once bound to ferric iron cefiderocol is able to undergo active transport into bacterial cells through iron channels in the outer cell membrane such as those encoded by the cirA and fiu genes in E. coli or the PiuA gene in P. aeruginosa. Once inside the cell, cefiderocol binds to and inhibits PBP3 with high affinity thereby preventing the linking of peptodoglycan layers via the pentapeptide bridge. PBP1a, 1b, 2,and 4 are also bound and inhibited by cefiderocol but with a lesser potency than PBP3 and are therefore expected to contribute less to its antibacterial effect.
- Primary indication
- Cefiderocol is indicated for the treatment of complicated urinary tract infections with or without pyelonephritis.Curator reviewed · 4 structured indications
- Formula / weight
- C30H34ClN7O10S2 · 752.21 g/mol (avg)
- First approval
- United States, 2020 · European Union, 2021
- Code names
- GSK 2696266 · RSC 649266 · S-649266
- Brand names
- Fetcroja
- Fetroja
Resolves to
DBPPRLRVDVJOCL-FQRUVTKNSA-NSMILES[H][C@]12SCC(C[N+]3(CCNC(=O)C4=C(Cl)C(O)=C(O)C=C4)CCCC3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC(C)(C)C(O)=O)\C1=CSC(N)=N1)C([O-])=OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Cefiderocol, and which of those have an active Phase 3 trial?